Teva Pharmaceutical Industries Ltd (TEVA): Today's Featured Drugs Winner

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

Teva Pharmaceutical Industries ( TEVA) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day up 0.1%. By the end of trading, Teva Pharmaceutical Industries rose 39 cents (1%) to $38.94 on average volume. Throughout the day, 5.2 million shares of Teva Pharmaceutical Industries exchanged hands as compared to its average daily volume of 5.3 million shares. The stock ranged in a price between $38.53-$38.94 after having opened the day at $38.62 as compared to the previous trading day's close of $38.55. Other companies within the Drugs industry that increased today were: Atossa Genetics ( ATOS), up 25.2%, StemCells ( STEM), up 21%, ZIOPHARM Oncology ( ZIOP), up 17.5%, and Albany Molecular Research ( AMRI), up 15.7%.
  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Teva Pharmaceutical Industries Limited develops, manufactures, and sells pharmaceutical products worldwide. Teva Pharmaceutical Industries has a market cap of $33.57 billion and is part of the health care sector. The company has a P/E ratio of 10.5, below the S&P 500 P/E ratio of 17.7. Shares are up 3.6% year to date as of the close of trading on Monday. Currently there are 12 analysts that rate Teva Pharmaceutical Industries a buy, no analysts rate it a sell, and 14 rate it a hold.

TheStreet Ratings rates Teva Pharmaceutical Industries as a hold. The company's strengths can be seen in multiple areas, such as its reasonable valuation levels, good cash flow from operations and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and generally higher debt management risk.

On the negative front, Celsion Corporation ( CLSN), down 10.4%, Apricus Biosciences ( APRI), down 9.7%, Pernix Therapeutics Holdings ( PTX), down 9.5%, and Rexahn Pharmaceuticals ( RNN), down 8.8%, were all laggards within the drugs industry with Alexion Pharmaceuticals ( ALXN) being today's drugs industry laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE.
null

If you liked this article you might like

S&P 500 and Dow Score Records With Wall Street Upbeat Ahead of Fed

S&P 500 and Dow on Track for Records With Markets in Good Mood Ahead of Fed

S&P 500 and Dow Aim for New Records With Broad-Based Gains Ahead of Fed

Dow and S&P 500 Reach New Intraday Highs With Markets in Good Mood Ahead of Fed

Teva's New CEO Brings This Secret Weapon